Vault-13

PROCAPS GROUP SA PROCF

SHS · Common Stock · CUSIP L7756P102

10 institutional holders +2 vs Q1 2023
71,98572.0k shares reported held*
$342.5kreported value*
3 new 1 added 2 reduced 1 sold out net sold ≈ $590.4k (-148.7k shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $4.76.

Trends to Q2 2023

Institutional holders

Managers reporting a position, each quarter

0510Q3 22: 9Q4 22: 8Q1 23: 8Q2 23: 1010Q3 22Q4 22Q1 23Q2 23
Numbers
QuarterHolders
Q3 20229
Q4 20228
Q1 20238
Q2 202310

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
404Q4 22: 2 bought or addedQ4 22: 4 cut or sold outQ4 22Q1 23: 4 bought or addedQ1 23: 4 cut or sold outQ1 23Q2 23: 4 bought or addedQ2 23: 3 cut or sold outQ2 23
Numbers
QuarterBought or addedCut or sold out
Q4 202224
Q1 202344
Q2 202343

Biggest buyers

Activest Wealth Management New +10,000+10.0k
STATE STREET CORP Added +405+405
JPMORGAN CHASE & CO New +304+304
UBS Group AG New +1+1

Biggest sellers

COMPASS GROUP LLC Reduced -140,410-140.4k
MILLENNIUM MANAGEMENT LLC Reduced -18,948-18.9k
Tower Research Capital LLC (TRC) Sold out -54-54

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Flying Fish Ventures L.P. 13D · may seek influence new · filed 2025-04-22
Stated purposeThe information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Persons acquired the securities covered by this Schedule 13D held by them for investment purposes and intend to review their investment in the Issuer on a continuing basis. Subject to the terms of the Shareholder Agreement discussed in Item 6 below, depending on various factors, including but not limited to the Issuer's financial position and strategic direction, price levels of the Ordinary Shares, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Issuer as they deem appropriate, including changing their current intentions, w… Full filing
84.4% new 2.1bn 2025-04-22
Saint Thomas Commercial S.A. 13D · may seek influence new · filed 2025-04-22
Stated purposeThe information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Persons acquired the securities covered by this Schedule 13D held by them for investment purposes and intend to review their investment in the Issuer on a continuing basis. Subject to the terms of the Shareholder Agreement discussed in Item 6 below, depending on various factors, including but not limited to the Issuer's financial position and strategic direction, price levels of the Ordinary Shares, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Issuer as they deem appropriate, including changing their current intentions, … Full filing
84.4% new 2.1bn 2025-04-22
Hoche Partners Pharma Holding S.A. 13D · may seek influence filed 2025-04-16
Stated purposeItem 4 of the Schedule 13D is amended and supplemented as follows: On April 9, 2025, the Company and Hoche entered into a Subscription and Conversion Agreement pursuant to which Hoche irrevocably elected to convert all of its remaining outstanding obligations under the Note Subscription Agreement into Ordinary Shares and receive the Warrant in connection with such conversion. The Note Subscription Agreement, originally entered into on November 29, 2024, as amended by that certain Amendment No. 1 dated April 3, 2025, provided for the issuance of Secured Convertible Notes to Hoche in a principal amount of $38,548,333.33. The notes were convertible into Ordinary Shares of the Company, par value $0.01 per share, in accordance with the terms of the Note Subscription Agreement. Pursuant to th… Full filing
84.4% 2.1bn 2025-04-16
Becaril S.A. 13D · may seek influence new · filed 2025-04-28
Stated purposeThe information set forth under Item 3 is incorporated by reference herein. On April 9, 2025, the Reporting Person acquired 325,109,560 Ordinary Shares (including shares issuable upon the exercise of a warrant) pursuant to the following transactions: (A) The Reporting Person acquired 299,560,430 Ordinary Shares for a purchase price per share of $0.06313, pursuant to a Subscription Agreement (the "Subscription Agreement") dated April 3, 2025, by and among the Company, the Reporting Person and Chemo Project, S.A. ("Chemo"). (B) The Reporting Person, in exchange for $362,916.67, acquired (i) $362,916.67 aggregate principal amount of secured convertible notes of the Company and the interest accrued thereunder (the "Notes") from Hoche Partners Pharma Holding S.A. ("Hoche") pursuant to an A… Full filing
53.0% new 1.3bn 2025-04-28
Chemo Project, S.A. 13D · may seek influence new · filed 2025-04-25
Stated purposeThe information set forth under Item 3 is incorporated by reference herein. On April 9, 2025, the Reporting Person acquired 325,109,560 Ordinary Shares (including shares issuable upon the exercise of a warrant) pursuant to the following transactions: (A) The Reporting Person acquired 299,560,430 Ordinary Shares for a purchase price per share of $0.06313, pursuant to a Subscription Agreement (the "Subscription Agreement") dated April 3, 2025, by and among the Company, the Reporting Person and Becaril S.A. ("Becaril"). (B) The Reporting Person, in exchange for $362,916.67, acquired (i) $362,916.67 aggregate principal amount of secured convertible notes of the Company and the interest accrued thereunder (the "Notes") from Hoche Partners Pharma Holding S.A. ("Hoche") pursuant to an Assign… Full filing
53.0% new 1.3bn 2025-04-25

Holders, Q2 2023

#ManagerLocationShares Value% of their portfolioChangeShares change
1 MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio NEW YORK, NY 21,43221.4k $85.1k $85.1k 0.00% Reduced -18.9k -18,948
2 GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio BOSTON, MA 21,22321.2k $84.3k $84.3k 0.00% Unchanged
3 STATE STREET CORP 0.00% of their portfolio BOSTON, MA 14,92814.9k $59.3k $59.3k 0.00% Added +405 +405
4 Activest Wealth Management 0.07% of their portfolio AVENTURA, FL 10,00010.0k $96.4k $96.4k 0.07% New
5 COMPASS GROUP LLC 0.01% of their portfolio NEW YORK, NY 3,9584.0k $15.7k $15.7k 0.01% Reduced -140.4k -140,410
6 JPMORGAN CHASE & CO 0.00% of their portfolio NEW YORK, NY 304304 $1.2k $1.2k 0.00% New
7 MORGAN STANLEY 0.00% of their portfolio NEW YORK, NY 100100 $430 $430 0.00% Unchanged
8 CLEAR STREET LLC 0.00% of their portfolio NEW YORK, NY 3939 $168 $168 0.00% Unchanged
9 UBS Group AG 0.00% of their portfolio ZURICH, V8 11 $4 $4 0.00% New
10 CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio BIRMINGHAM, AL 00 $0 $0 0.00% Unchanged